Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) but lowers the price target from $42 to $41.

August 09, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Cartesian Therapeutics but lowers the price target from $42 to $41.
The maintained Buy rating suggests continued confidence in Cartesian Therapeutics' prospects, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100